57818-44-7
中文名稱
偽-HYDROXYLINOLEIC ACID
英文名稱
Voxilaprevir
CAS
57818-44-7
分子式
C18H32O3
分子量
296.44
MOL 文件
57818-44-7.mol
更新日期
2026/06/04 14:21:39
57818-44-7 結(jié)構(gòu)式
基本信息
中文別名
Α-羥基油酸偽-HYDROXYLINOLEIC ACID
英文別名
ABTL0812ABTL-0812
ABTL 0812
ABTL0812 (ABTL 0812
α-Hydroxylinoleic acid
2-hydroxylinoleic acid)
ABTL 0812
2-HYDROXYLINOLEIC ACID
9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-
(9~{Z},12~{Z})-2-hydroxyoctadeca-9,12-dienoic acid
物理化學性質(zhì)
沸點409.7±30.0 °C(Predicted)
密度0.970±0.06 g/cm3(Predicted)
儲存條件-20°C儲存
溶解度DMSO: 5 mg/mL (16.87 mM)
酸度系數(shù)(pKa)3.85±0.21(Predicted)
形態(tài)Liquid
顏色Colorless to light yellow
偽-HYDROXYLINOLEIC ACID價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-U00141 | 偽-HYDROXYLINOLEIC ACID ABTL-0812 | 57818-44-7 | 1 mg | 1300元 |
| 2026/06/05 | HY-U00141 | 偽-HYDROXYLINOLEIC ACID ABTL-0812 | 57818-44-7 | 5mg | 3300元 |
| 2026/06/05 | HY-U00141 | 偽-HYDROXYLINOLEIC ACID ABTL-0812 | 57818-44-7 | 10mg | 5500元 |
常見問題列表
生物活性
ABTL0812 (α-Hydroxylinoleic acid, LP-10218, SCLN-0812) 可在肺鱗癌細胞系中通過誘導TRIB3的過表達和激活自噬來抑制 Akt/mTOR 軸。ABTL0812 還可誘導 AMPK 激活和 ROS 積累。靶點
| Target | Value |
|
Akt
() | |
|
mTOR
() |
體外研究
ABTL-0812 (ABTL0812; 10-100 μM; 48 hours) inhibits cell viability of squamous NSCLC H157 cells.
Compared with squamous NSCLC H157 cells, human lung fibroblast cell line MRC-5 are resistant to ABTL0812 treatment.
Cell Viability Assay
| Cell Line: | Human lung fibroblast MRC5 and squamous non-small cell lung (NSCLC) H157 cells |
| Concentration: | 10, 30, 100 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited cell viability of squamous NSCLC H157 cells, not lung fibroblast cell line MRC-5. |
體內(nèi)研究
ABTL-0812 (ABTL0812; 120 mg/kg; oral gavage; 5 times per week; for 33 d) induces ER stress in human lung and pancreatic xenografts.
ABTL-0812 induces hallmarks of ER stress in vivo. ABTL-0812 increases ATF4 and HSPA5 expression in mice bearing MiaPaca2 and A549 xenograft, respectively.
| Animal Model: | Athymic female nude mice bearing MiaPaca2 and A549 xenograft models |
| Dosage: | 120 mg/kg |
| Administration: | Administered by oral gavage; 5 times per week for 33 days |
| Result: | Induced ER stress in human lung and pancreatic xenografts. |